Clinical Trials Logo

Recurrent Lymphoma clinical trials

View clinical trials related to Recurrent Lymphoma.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03291938 Completed - Clinical trials for Pancreatic Ductal Adenocarcinoma

IACS-010759 in Advanced Cancers

Start date: November 13, 2017
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of oxidative phosphorylation inhibitor IACS-010759 (IACS-010759) in treating patients with lymphoma that has come back (relapsed) or does not respond to treatment (refractory) or solid tumors that have spread to other places in the body (advanced/metastatic) or cannot be removed by surgery (unresectable). IACS-010759 may stop the growth of cancer or tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT03229278 Completed - Lymphoma Clinical Trials

Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma

Start date: October 3, 2017
Phase: Phase 1
Study type: Interventional

This phase I trial studies the best dose and side effects of trigriluzole in combination with nivolumab and pembrolizumab in treating patients with solid malignancies or lymphoma that has spread to other places in the body or cannot be removed by surgery. Trigriluzole may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as nivolumab and pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Giving trigriluzole in combination with nivolumab and pembrolizumab may work better at treating patients with solid malignancies or lymphoma.

NCT ID: NCT02780804 Completed - Clinical trials for Refractory Malignant Solid Neoplasm

Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors

Start date: January 6, 2017
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of entinostat in treating pediatric patients with solid tumors that have come back or have not responded to treatment. Entinostat may block some of the enzymes needed for cell division and it may help to kill tumor cells.

NCT ID: NCT02343718 Completed - Solid Tumours Clinical Trials

Vinblastine and Temsirolimus in Pediatrics With Recurrent or Refractory Lymphoma or Solid Tumours Including CNS Tumours

Start date: June 24, 2015
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the best dose of vinblastine that can be given with a new drug, temsirolimus.